Cytosorbents Corp
NASDAQ:CTSO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.7
2.02
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CTSO stock under the Base Case scenario is 1.91 USD. Compared to the current market price of 1.42 USD, Cytosorbents Corp is Undervalued by 26%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Cytosorbents Corp
Run backtest to discover the historical profit from buying and selling CTSO based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Cytosorbents Corp
Balance Sheet Decomposition
Cytosorbents Corp
Current Assets | 22m |
Cash & Short-Term Investments | 8.5m |
Receivables | 7.8m |
Other Current Assets | 5.7m |
Non-Current Assets | 31.5m |
PP&E | 21.2m |
Other Non-Current Assets | 10.3m |
Current Liabilities | 10.3m |
Accounts Payable | 3m |
Accrued Liabilities | 6m |
Other Current Liabilities | 1.3m |
Non-Current Liabilities | 26.4m |
Long-Term Debt | 13.7m |
Other Non-Current Liabilities | 12.7m |
Earnings Waterfall
Cytosorbents Corp
Revenue
|
37.2m
USD
|
Cost of Revenue
|
-13.2m
USD
|
Gross Profit
|
24m
USD
|
Operating Expenses
|
-48.1m
USD
|
Operating Income
|
-24.1m
USD
|
Other Expenses
|
-1.4m
USD
|
Net Income
|
-25.5m
USD
|
Free Cash Flow Analysis
Cytosorbents Corp
USD | |
Free Cash Flow | USD |
CTSO Profitability Score
Profitability Due Diligence
Cytosorbents Corp's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Cytosorbents Corp's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
CTSO Solvency Score
Solvency Due Diligence
Cytosorbents Corp's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Score
Cytosorbents Corp's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTSO Price Targets Summary
Cytosorbents Corp
According to Wall Street analysts, the average 1-year price target for CTSO is 4.59 USD with a low forecast of 1.01 USD and a high forecast of 10.5 USD.
Shareholder Yield
Current shareholder yield for CTSO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
CTSO Price
Cytosorbents Corp
Average Annual Return | -6.21% |
Standard Deviation of Annual Returns | 77.97% |
Max Drawdown | -94% |
Market Capitalization | 77.1m USD |
Shares Outstanding | 54 306 400 |
Percentage of Shares Shorted | 2.75% |
Ownership
CTSO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Monmouth Junction, New Jersey and currently employs 221 full-time employees. The company went IPO on 2005-06-17. The firm is engaged in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via its polymer adsorption technology. The firm's lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy and pancreatitis. Its other products include animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. The firm's product candidates under development includes CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent and porous polymer beads.
Contact
IPO
Employees
Officers
The intrinsic value of one CTSO stock under the Base Case scenario is 1.91 USD.
Compared to the current market price of 1.42 USD, Cytosorbents Corp is Undervalued by 26%.